MHRA’s Rawlins Says New Approach Needed For Clinical Trials
This article was originally published in The Pink Sheet Daily
The chairman of Britain’s regulator the MHRA says clinical trials need more adaptive designs using smaller patient numbers if drug development costs are to be cut and innovative therapies made more accessible more quickly.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.
Investors during Roche’s first-quarter update 21 April will be looking for guidance on the strong growth of biosimilar competition to its cancer mainstays and how this may be offset by the group’s pipeline.